Products & Pipeline
BirchBioMed is actively advancing a robust portfolio of innovative treatments currently in mid-to-late stage clinical trials. We are developing a diverse range of applications across three key technologies: topical creams of Kynurenic Acid (KynA), systemic administration of KynA, and a pioneering one-time delivery of APCs in combination with systemic KynA administration. These products are being rigorously tested in eight distinct programs, targeting a variety of indications to meet critical healthcare needs in fibrosis and specific subsets of autoimmune disorders.
Our market reach extends across North America, Europe, and Southeast Asia, positioning BirchBioMed to impact a broad spectrum of global health markets with cutting-edge, clinically advanced therapies.
Topical Creams
BirchBioMed’s topical creams, formulated with Kynurenic Acid (KynA), are designed to target skin-related conditions effectively. This line of topical treatments is in clinical development for five different indications, leveraging KynA’s properties to enhance ECM remodeling and reduce inflammation directly at the site of application.
Systemic Administration
The systemic administration of Kynurenic Acid (KynA) represents a groundbreaking approach in the treatment of systemic fibrotic conditions. Currently in clinical trials, this method delivers KynA directly into the bloodstream, enabling it to target life-threatening organ fibrosis.
One-Time Delivery of APCs in Combination with Systemic Delivery of KynA
Combining systemic administration of Kynurenic Acid with one-time delivery of APCs, BirchBioMed is developing a pioneering therapeutic approach tailored for a subset of autoimmune disorders like Type 1 Diabetes and Alopecia Areata.
